奧瑞金(002701.SZ):終止與專業投資機構共同投設基金事項
格隆匯6月14日丨奧瑞金(002701.SZ)公佈,此前披露,公司與廈門傲彬私募股權投資基金管理有限公司、廈門瑞彬消費產業投資基金合夥企業(有限合夥)共同投資設立廈門傲盛產業投資基金合夥企業(有限合夥)(以下簡稱“基金”、“合夥企業”,最終名稱以工商登記為準),主要投資方向為食品飲料生產、金屬包裝、快速消費品、大健康等領域。合夥企業認繳出資總額為人民幣3億元,公司作為有限合夥人以自有資金出資人民幣2.697億元,佔合夥企業認繳出資比例的89.9%。
因合作項目實施的外部條件尚不完全確定,經友好、深入溝通,各方經過審慎研判,一致同意終止本次共同投資事項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.